Becton, Dickinson and Company (NYSE:BDX) Hits New 1-Year High – Here’s Why

Posted by Francis Steltz on Aug 27th, 2026

Becton, Dickinson and Company (NYSE:BDX – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $193.07 and last traded at $190.5840, with a volume of 1310991 shares. The stock had previously closed at $192.00.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BDX. Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Barclays lifted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research note on Monday, July 6th. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $185.67.

Get Our Latest Stock Analysis on BDX

Becton, Dickinson and Company Stock Performance

The stock has a fifty day moving average price of $164.35 and a 200 day moving average price of $160.49. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market cap of $52.41 billion, a price-to-earnings ratio of 57.30, a price-to-earnings-growth ratio of 13.38 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the firm posted $3.68 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,704 shares of company stock worth $1,963,618 in the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors have recently bought and sold shares of BDX. California State Teachers Retirement System lifted its position in shares of Becton, Dickinson and Company by 14,668.6% in the 2nd quarter. California State Teachers Retirement System now owns 69,907,953 shares of the medical instruments supplier’s stock worth $10,579,171,000 after purchasing an additional 69,434,598 shares during the period. Auto Owners Insurance Co grew its holdings in Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares during the period. BlackRock Inc. bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth about $3,721,533,000. Wellington Management Group LLP grew its stake in Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after purchasing an additional 5,174,944 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock worth $769,397,000 after purchasing an additional 4,137,888 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.